

ARGENX SE SPON ADR EACH REP 1 ORD SHS

ISIN: **US04016X1019** WKN: **04016X101**

Overview

| | |
|---------------------|---|
| 2024/10/18 08:05:58 | |
| Price | 500.00 EUR |
| Difference | ↗ 0.81% (4.00) |

| | |
|---------------------------|------------------------------------|
| General attributes | |
| ISIN | US04016X1019 |
| Symbol | ARGX |
| Exchange | Munich |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 30,460 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |

| | |
|--------------------|------------|
| Market data | |
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 500.00 EUR |
| High | 500.00 EUR |
| Low | 500.00 EUR |
| Close (prev. day) | 496.00 EUR |
| VWAP | 352.00 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 2 |
| Last size | 0 |

| | |
|----------------------------|---|
| Futures and Options | |
| Related Futures | - |
| Related Options | - |

| | |
|---|--------------------------|
| PDF Downloads | |
| Company report: ARGENX SE SPON ADR EACH REP 1 ORD SHS | Download |



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | | on market | |
|------------|--|-----------------------|--------------------------|
| Date | | Headline | Download |
| 2024/09/27 | | Global Equity Ratings | Download |
| 2024/09/11 | | Global Equity Ratings | Download |
| 2024/09/05 | | Global Equity Ratings | Download |
| 2024/08/12 | | Global Equity Ratings | Download |
| 2024/07/24 | | Global Equity Ratings | Download |

Details

2024/10/18 08:05:58

Price

500.00 EUR

Difference ▲ 0.81% (4.00)

General attributes

ISIN US04016X1019

Symbol ARGX

Exchange Munich

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 30,460 EUR

Benchmark AMSTERDAM EXCHANGES INDEX

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 500.00 EUR

High 500.00 EUR

Low 500.00 EUR

Close (prev. day) 496.00 EUR

VWAP 352.00 EUR

Volume (pcs) 0

Trading volume 0.00

Number of trades 2

Last size 0

Performance and Risk

| | 6m | 1Y | 3Y |
|--------------------|---------|--------|---------|
| Perf (%) | +45.35% | +6.38% | +95.31% |
| Perf (abs.) | +156.00 | +30.00 | +244.00 |
| Beta | 0.39 | 0.46 | 0.42 |
| Volatility | 29.38 | 41.81 | 38.74 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 494.40 EUR (0) |
| Ø price 30 days Ø volume 30 days (pcs.) | 485.33 EUR (0) |
| Ø price 100 days Ø volume 100 days (pcs.) | 444.00 EUR (2) |
| Ø price 250 days Ø volume 250 days (pcs.) | 402.50 EUR (1) |
| YTD High date | 500.00 EUR (2024/10/18) |
| YTD Low date | 328.00 EUR (2024/03/21) |
| 52 Weeks High date | 500.00 EUR (2024/10/18) |
| 52 Weeks Low date | 304.00 EUR (2023/12/21) |

Arbitrage views

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------|------------|-------|------------|-----------------------|------------------|
| Stuttgart | 2024/10/18 | 13:25 | 498.00 EUR | 0.00 | 8 |
| Nasdaq | 2024/10/18 | 22:00 | 565.00 USD | 209.35 | 7,296 |
| Munich | 2024/10/18 | 08:05 | 500.00 EUR | 0.00 | 2 |
| Hanover | 2024/10/18 | 17:25 | 500.00 EUR | 0.00 | 4 |
| Hamburg | 2024/10/18 | 17:25 | 500.00 EUR | 0.00 | 4 |

| | | | | | | | |
|-------------|----------------|-------|--------|-----|------|--|----|
| | 18 | | | | | | |
| Frankfurt | 2024/10/ 18 | 08:03 | 496.00 | EUR | 0.00 | | 2 |
| Duesseldorf | 2024/10/ 18 | 08:12 | 496.00 | EUR | 0.00 | | 3 |
| Berlin | 2024/10/ 18 | 21:52 | 520.00 | EUR | 0.00 | | 19 |

Company profile

Company Logo



Contact Details

ARGENX SE

--

Laarderhoogtweg 25 - 1101 EB Amsterdam

Telefon: +31-76-303-04-88

Fax: +

E-mail: info@argenx.com

PDF Downloads

Company report: ARGENX SE SPON
ADR EACH REP 1 ORD SHS



Company Profile

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Members of Management Board

| | |
|----------------------|-------------------------------|
| Tim Van Hauwermeiren | Chairman of Managing Board |
| Andria Wilk | Member of Executive Committee |
| Arjen Lemmen | Member of Executive Committee |
| Beth DelGiacco | Member of Executive Committee |
| Filip Borgions | Member of Executive Committee |
| Karen Massey | Member of Executive Committee |
| Karl Gubitz | Member of Executive Committee |
| Luc Truyen | Member of Executive Committee |
| Malini Moorthy | Member of Executive Committee |
| Marc Schorpion | Member of Executive Committee |
| Peter Ulrichs | Member of Executive Committee |

Board of directors

| | |
|------------------------|-------------------------------|
| Peter K. M. Verhaeghe | Chairman of Supervisory Board |
| Ana Cespedes | Member of Supervisory Board |
| Brian Kotzin | Member of Supervisory Board |
| Joseph deBethizy | Member of Supervisory Board |
| Pamela Klein | Member of Supervisory Board |
| Anthony Adam Rosenberg | Member of Supervisory Board |
| Camilla Sylvest | Member of Supervisory Board |
| James Daly | Member of Supervisory Board |
| Steve Krognes | Member of Supervisory Board |